In-vitro Study of Multifunctional PLGA-SPION Nanoparticles Loaded with Gemcitabine as Radiosensitizer Used in Radiotherapy

被引:14
作者
Hamzian, Nima [1 ]
Hashemi, Maryam [2 ]
Ghorbani, Mahdi [3 ]
Aledavood, Seyed Amir [4 ]
Ramezani, Mohammad [5 ,6 ]
Toossi, Mohammad Hossein Bahreyni [7 ]
机构
[1] Shahid Sadoughi Univ Med Sci, Fac Med, Dept Med Phys, Yazd, Iran
[2] Mashhad Univ Med Sci, Nanotechnol Res Ctr, Inst Pharmaceut Technol, Mashhad, Razavi Khorasan, Iran
[3] Shahid Beheshti Univ Med Sci, Fac Med, Dept Biomed Engn & Med Phys, Tehran, Iran
[4] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Razavi Khorasan, Iran
[5] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Inst Pharmaceut Technol, Mashhad, Razavi Khorasan, Iran
[6] Mashhad Univ Med Sci, Dept Pharmaceut Biotechnol, Sch Pharm, Mashhad, Razavi Khorasan, Iran
[7] Mashhad Univ Med Sci, Med Phys Res Ctr, Fac Med, Mashhad, Razavi Khorasan, Iran
来源
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH | 2019年 / 18卷 / 04期
基金
美国国家科学基金会;
关键词
Multifunctional drug delivery system; SPION-PLGA; Gemcitabine; Radiotherapy; Radiosensitizer; CANCER-CELLS; DELIVERY; FE3O4; VIVO;
D O I
10.22037/ijpr.2019.14050.12131
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study aimed to modify the biological response of cells to ionizing radiation by combination therapy using radio-sensitizer agent and anticancer drug. Super paramagnetic iron oxide nanoparlicles (SPIONs) were prepared and used with gemcitabine (Gem). These two agents were encapsulated simultaneously intopoly (D, L-lactic-co-glycolic acid) (PLGA) to form multifunctional drug delivery system. The physicochemical characteristics of the nanoparticles (NPs) were studied. The dose enhancement ratio (DER) of various treatment groups was calculated and compared using human breast cancer cell line (MCF-7). The DER for PLGA-SPION-Gem was the highest at 1 Gy(60)Co (3.18). Cumulative effect from simultaneous use of two radiosensitizer (Gem and SPIONs) was observed. Thus, we have successfully developed PLGA NPs loaded with gemcitabine and SPIONas a radiosensitizersystem which potentially could be used in radiotherapy.
引用
收藏
页码:1694 / 1703
页数:10
相关论文
共 34 条
  • [1] NanoCipro encapsulation in monodisperse large porous PLGA microparticles
    Arnold, Matthew M.
    Gonnan, Enic M.
    Schieber, Loren J.
    Munson, Eric J.
    Berkland, Cory
    [J]. JOURNAL OF CONTROLLED RELEASE, 2007, 121 (1-2) : 100 - 109
  • [2] Effect of preparative variables on the properties of poly(dl-lactide-co-glycolide) methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery
    Beletsi, A
    Leontiadis, L
    Klepetsanis, P
    Ithakissios, DS
    Avgoustakis, K
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 182 (02) : 187 - 197
  • [3] Chen BA, 2009, INT J NANOMED, V4, P65
  • [4] Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes
    Cheng, Fong-Yu
    Wang, Saprina Ping-Hsien
    Su, Chio-Hao
    Tsai, Tsung-Liu
    Wu, Ping-Ching
    Shieh, Dar-Bin
    Chen, Jyh-Horng
    Hsieh, Patrick Ching-Ho
    Yeh, Chen-Sheng
    [J]. BIOMATERIALS, 2008, 29 (13) : 2104 - 2112
  • [5] Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)
    Fields, MT
    Eisbruch, A
    Normolle, D
    Orfall, A
    Davis, MA
    Pu, AT
    Lawrence, TS
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (03): : 785 - 791
  • [6] Chemosensitization and radiosensitization of tumors by plant polyphenols
    Garg, AK
    Buchholz, TA
    Aggarwal, BB
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2005, 7 (11-12) : 1630 - 1647
  • [7] Girdhani S, 2005, J Cancer Res Ther, V1, P129
  • [8] Grégoire V, 1999, ONCOL REP, V6, P949
  • [9] Hamzian N, 2017, IRAN J PHARM RES, V16, P8
  • [10] Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma
    Householder, Kyle T.
    DiPerna, Danielle M.
    Chung, Eugene P.
    Wohlleb, Gregory M.
    Dhruv, Harshil D.
    Berens, Michael E.
    Sirianni, Rachael W.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 479 (02) : 374 - 380